{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of 95% CI was not estimate due to limited number of events","groupId":"OG000","lowerLimit":"1.4","upperLimit":"NA","value":"7.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Duration of response was defined as the time from first documented evidence of PR or better, to the time when disease progression (PD) is documented per IMWG response criteria; or death due to PD occurs among participants who achieve an overall response, i.e. confirmed PR or better. PD= Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \\>= 0.5 g/dL; Serum M-protein increase \\>= 1 g/dL if the lowest M-component was \\>=5 g/dL; Urinary M-protein (absolute increase must be \\>= 200 mg per 24 h). PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥ 90% or to \\<200 mg/24 h.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered belantamab mafodotin with recommended phase 2 dose (RP2D) of 2.5 mg/kg in combination with 200 mg of pembrolizumab via IV infusion on Day 1 of each 21-day Cycle up to until disease progression, intolerable toxicity, informed consent withdrawal, or for a maximum of 35 cycles.","id":"OG000","title":"Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion"}],"paramType":"MEDIAN","populationDescription":"All Treated Population. Only those participants with data available at specified time points have been analyzed.","reportingStatus":"POSTED","timeFrame":"Up to approximately 178 weeks","title":"Part 2 - Duration of Response","type":"SECONDARY","unitOfMeasure":"Months"}